SILVIU ITESCU, MD
Osteopathic Medicine at Fort Washington Ave, New York, NY

2004013, Jul 8, 2004

Mar 4, 2003

10/220554

Silviu Itescu - New York NY, US

A61K045/00, A61K038/19, A61K038/20

424/085100, 424/093700

The present invention provides a method of stimulating vasculogenesis of myocardial infarct damaged tissue in a subject comprising: (a) removing stem cells from a location in the subject; (b) recovering endothelial progenitor cells in the stem cells; (c) introducing the endothelial progenitor cells from step (b) into a different location in the subject such that the precursors migrate to and stimulate revascularization of the tissue. The stem cells may be removed directly or by mobilization. The endothelial progenitor cells may be expanded before introduction into the subject. The present invention further provides a method of inducing angiogenesis in peri-infarct tissue. The present invention further provides a method of selectively increasing the trafficking of human bone marrow-derived endothelial cell precursors to the site of tissue damaged by ischemic injury which comprises: (a) administering endothelial progenitor cells to a subject; (b) administering chemokines to the subject so as to thereby attract endothelial cell precursors to the ischemic tissue. The present invention provides a method of stimulating vasculogenesis or angiogenesis of myocardial infarct damaged tissue in a subject comprising injecting allogeneic stem cells into a subject. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising any of the instant methods. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF or anti-CXCR4 antibody into the subject in order to mobilize endothelial progenitor cells.

2004024, Dec 9, 2004

Oct 23, 2003

10/693480

Silviu Itescu - New York NY, US

A61K038/20, A61K038/18

424/085200, 128/898000, 514/012000

This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.

2006021, Sep 21, 2006

May 19, 2006

11/437141

Silviu Itescu - New York NY, US

C12Q 1/68, G01N 33/53

435006000, 435007240

The present invention relates to a method for predicting whether or not transplant recipients are likely to reject tissue allografts. It is based, at least in part, on the discovery that based on analysis of three immunologic factors, cardiac transplant recipients could be classified into risk categories for progression to high-grade rejection. The present invention, by enabling a determination of the risk for high-risk rejection in a transplant patient, reduces unnecessary diagnostic and therapeutic procedures in low risk patients and clinical intervention in patients who would most benefit.

7662794, Feb 16, 2010

Apr 23, 2003

10/512496

Silviu Itescu - New York NY, US

The Trustees of Columbia University in the City of New York - New York NY

C07H 21/04, A01N 43/04, A61K 31/70

514 44, 536 231, 536 243, 536 2433, 536 245

The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1, and methods of treating diseases by such. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes, antisense oligonucleotides, or other inhibitors of PAI-1 expression as active ingredients.

7662392, Feb 16, 2010

Sep 22, 2005

11/234879

Silviu Itescu - New York NY, US

The Trustees of Columbia University in the City of New York - New York NY

A61K 38/18, A61K 38/16, C07K 14/475

4241981, 4241841, 514 2, 514 12, 530399

This invention provides methods of improving myocardial function in a subject after ischemic injury comprising administering G-CSF or SDF-1 to the subject.

2003019, Oct 23, 2003

Apr 23, 2002

10/128738

Silviu Itescu - New York NY, US

A61K048/00

514/044000

This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder. This invention further provides the instant method wherein the agent is human endothelial progenitor cells. This invention also provides methods of determining the susceptibility of a cardiomyocyte in a subject to apoptosis.

2003019, Oct 23, 2003

Apr 23, 2002

10/128706

Silviu Itescu - New York NY, US

A61K048/00, C07H021/02

514/044000, 536/023100

The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes and antisense oligonucleotides as active ingredients.